Related Experiment Video

Updated: Oct 13, 2025

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.8K

Vedolizumab: An Emerging Treatment Option for Pediatric Inflammatory Bowel Disease

Pooja Shah, Danielle McDonald

    The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG
    |November 18, 2021
    PubMed

    Insights

    Vedolizumab offers a safe and moderately effective treatment option for pediatric inflammatory bowel disease. Further research is needed to establish optimal dosing and long-term safety in children.

    Area of Science:

    • Gastroenterology
    • Immunology
    • Pediatric Medicine

    Background:

    • Vedolizumab, an α4β7-integrin antagonist, is FDA-approved for adult inflammatory bowel disease (IBD).
    • Limited data exist for pediatric IBD patients, with current evidence from retrospective reviews and case series.

    Purpose of the Study:

    • To summarize existing literature on vedolizumab use in pediatric patients (< 18 years).
    • To provide recommendations for vedolizumab treatment in pediatric IBD.

    Main Methods:

    • A narrative review of studies identified through a PubMed search (January 2014-December 2020).
    • Keyword used: "vedolizumab".

    Main Results:

    • Vedolizumab demonstrates safety and moderate efficacy in pediatric IBD.
    • Literature suggests weight-based dosing regimens for pediatric use.
    • Long-term safety data are still limited.

    Conclusions:

    • Vedolizumab is a potential therapeutic option for refractory pediatric IBD.
    • Prospective, randomized trials are necessary to optimize dosing and confirm long-term safety.

    Keywords:
    Crohn's diseaseinflammatory bowel diseasepediatricsulcerative colitisvedolizumab

    More Related Videos

    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing07:38

    Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

    Published on: September 13, 2016

    8.5K
    In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

    In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

    Published on: January 22, 2020

    5.6K

    Related Concept Videos

    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    233
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    286
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
    238
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
    267
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
    259
    Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

    Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

    Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
    Diagnostic studies
    A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
    451